Adjunct corticosteroids in children hospitalized with community-acquired pneumonia

Pediatrics

Volumn 127, Issue 2, 2011, Pages

  Weiss, Anna K ^a   Hall, Matthew ^b   Lee, Grace E ^a   Kronman, Matthew P ^a,c   Sheffler Collins, Seth ^a   Shah, Samir S ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Child Health Corporation of America   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bacterial pneumonia; Child; Epidemiology; Pneumonia; Therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC PROCEDURE; GROUPS BY AGE; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; LENGTH OF STAY; MALE; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES;

EID: 79551510127     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0983     Document Type: Article

References (43)

1. Peck AJ, Holman RC, Curns AT, et al. Lower respiratory tract infections among American Indian and Alaska Native children and the general population of U.S. Children. Pediatr Infect Dis J. 2005;24(4):342-351
2. Shah SS, DiCristina CM, Bell LM, Ten Have T, Metlay JP. Primary early thoracoscopy and reduction in length of hospital stay and additional procedures among children with complicated pneumonia: results of a multicenter retrospective cohort study. Arch Pediatr Adolesc Med. 2008;162(7):675-681 (Pubitemid 351961561)
3. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002;34(4):434-440
4. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):1179-1186
5. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358(7):716-727
6. Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev. 2003;83(2):309-336
7. Cazzola M, Matera MG, Pezzuto G. Inflammation: a new therapeutic target in pneumonia. Respiration. 2005;72(2):117-126 (Pubitemid 40591521)
8. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis. 1990;141(2):471-501
9. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis. 1989;159(2):189-194
10. Yende S, Tuomanen EI, Wunderink R, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med. 2005;172(11):1440-1446
11. Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008;32(2):259-264
12. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med. 2002;165(7):983-991
13. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2007;(1):CD004405
14. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIVinfection. Cochrane Database Syst Rev. 2006;(3):CD006150
15. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14(1):218-220
16. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185(5):249-255
17. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe communityacquired pneumonia. Eur Respir J 2007;30(5):951-956 (Pubitemid 351194800)
18. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe communityacquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-248
19. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-982.
20. Salluh JI, Povoa P, Soares M, Castro-Faria-Neto HC, Bozza FA, Bozza PT. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care. 2008;12(3):R76
21. Lee KY, Lee HS, Hong JH, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006;41(3):263-268
22. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008;57(3):223-228
23. Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA. 2008;299(17):2048-2055
24. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49(9):1369-1376
25. Whittle J, Fine MJ, Joyce DZ, et al. Community-acquired pneumonia: can it be defined with claims data? Am J Med Qual. 1997;12(4):187-193
26. Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics. 2001;107(6). Available at: www.pediatrics.org/cgi/content/full/107/6/e99
27. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55
28. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-447 (Pubitemid 44316748)
29. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf. 2004;13(12):841-853
30. Imbens GW. Nonparametric estimation of average treatment effects under heterogeneity: a review. Rev Econ Stat. 2004;86:4-29
31. Greenland S. Introduction to regression modeling. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008:446-451
32. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787-2792
33. Michelow IC, Katz K, McCracken GH, Hardy RD. Systemic cytokine profile in children with community-acquired pneumonia. Pediatr Pulmonol. 2007;42(7):640-645
34. Gern JE, Martin MS, Anklam KA, et al. Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy. Pediatr Allergy Immunol. 2002;13(6):386-393
35. Johnston SL. Bronchial hyperresponsiveness and cytokines in virus-induced asthma exacerbations. Clin Exp Allergy. 1997;27(1):7-9
36. Johnston SL. The role of viral and atypical bacterial pathogens in asthma pathogenesis. Pediatr Pulmonol Suppl. 1999;18:141-143
37. Peebles RS JR, Sheller JR, Johnson JE, Mitchell DB, Graham BS. Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. J Med Virol. 1999;57(2):186-192
38. Martin RJ, Chu HW, Honour JM, Harbeck RJ. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am J Respir Cell Mol Biol. 2001;24(5):577-582 (Pubitemid 32442765)
39. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701-707
40. Biscardi S, Lorrot M, Marc E, et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis. 2004;38(10):1341-1346
41. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250
42. Tagliabue C, Salvatore CM, Techasaensiri C, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008;198(8):1180-1188
43. Chu HW, Campbell JA, Rino JG, Harbeck RJ, Martin RJ. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponsiveness in lungs of mice. J Infect Dis. 2004;189(6):1119-1127